aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months ...

By targeting RAD51, a key intracellular protein involved in DNA repair, the 3E10 antibody shows great promise for cancer treatment, particularly in cancers with defective DNA repair pathways.

Monoclonal antibodies, in particular immune checkpoint inhibitors ... of bsAbs targeting immunomodulatory checkpoints and highlights their applications in cancer immunotherapy.

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Three monoclonal antibodies (cetuximab, bevacizumab and panitumumab) have been approved for the treatment of colorectal cancer in the USA and a large number of other monoclonal antibodies are ...

Huang, B.T., Li, K.F., Wu, X.S., Zhang, F.Y. and Li, Y.P. (2025) Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, ...

was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal ... the 3E10 antibody shows great promise for cancer treatment, particularly ...

Medically reviewed by Doru Paul, MD Immunotherapy can boost your body’s immune response to cancer cells and hopefully kill ...

ADCs have three main elements: a monoclonal antibody (mAb ... meet the growing demand for enhanced efficacy and safety in cancer treatment. ADCs are designed as a form of "targeted chemotherapy ...

Request To Download Free Sample of This Strategic Report @ Catalysts of Market Growth: The buoyant growth trajectory of the global monoclonal antibodies market is propelled by a convergence of ...

NEW research has shown that anti-CGRP monoclonal antibodies (mAbs) are not associated with an increased cardiovascular ...